drugset / Trial / NCT07315087
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1
Recruiting
12 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Shanghai Xiniao Biotech Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Timeline
- Start
- 2026-01-01
- Primary completion
- 2029-01-01
- Completion
- 2029-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QT-019C | Cell therapy | — | Intravenous |